David F. Hale, Director at Oncternal Therapeutics, Inc. (ONCT), bought 980 shares at $9.04 ($9K) on 2024-02-23, disclosed to the SEC on 2024-02-27.
Open-market purchase of $9k ONCT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.04 | 266 | $2K | 27.1% |
| 2 | $9.04 | 714 | $6K | 72.9% |
| Total | $9.04 avg | 980 | $9K | 100% |
| Filing → |
| BIOC | SELL | 2020-06-12 | $645 | — | Filing → |
| BIOC | BUY | 2016-10-21 | $200K | — | Filing → |
| BIOC | BUY | 2016-05-05 | $50K | — | Filing → |